We wishh to inform you that the management of the company intends to engage in discussions with investors/analyst meet on 4th June, 2026 & 5th June, 2026 at Mumbai. Further, please note that no unpublished price sensitive information pertaning to the company will be shared at aforesaid meet.
we wish to inform you that ICRA Limited has vide its letter dated 26th May, 2026, re-affirmed its rating on the long term bank facility and instrumnet of Indraprasth Medical Corporation Limited at "[ICRA]AA(Stable)" and the short term rating at [ICRA]A1+.
We hereby submit copies of the public notice of the financial results, published on 13th May, 2026, in the "Financial Express", all India editions, in English Language and in " Jansatta", Delhi edition, in Hindi language.
the board of directors of the company inter-alia : 1. Approved the audited finacial results for the quater/year ended 31st March, 2026, 2. Reccomended a dividend @ 40% i.e., Rs 4 per equity shares for the finacial year 2025-2026, subject to approval of shareholders at the AGM of the company.
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that a meeting of the Board of Directors of the Company will be held on Tuesday, 12th May, 2026, inter alia: - a) to consider and approve the audited financial results for the quarter/ year ended 31st March, 2026; and b) to consider and recommend dividend, if any, on equity shares of the Company for the financial year 2025-26. This is for your information and record.
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyIndraprastha Medical Corporation Ltd 2CIN NO.L24232DL1988PLC030958 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRIYA RANJAN Designation: AVP CORPORATE AFFAIRS AND LEGAL EmailId: priya_ranjan@apollohosppitals.com Name of the Chief Financial Officer: C P TYAGI Designation: CHEIF FINANCIAL OFFICER EmailId: tyagi@apollohospitals.com Date: 23/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Please find herewith a certificate dated 1st April, 2026, issued by M/s MUFG Intime India Private Limited, Registrar & Transfer Agent of the Company, for the quarter ended 31st March, 2026.
We enclose herewith copies of the public notice of the request received under Special window for re-lodgment of transfer request for physical shares, published on 7th April, 2026, in the Financial express, all India editions, in English Language and in Jansatta, Delhi edition, in Hindi language. This is for your information and record.
We hereby inform you that Mr. Vinayak Chatterjee (DIN: 00008933) has completed his tenure viz. second term of five consecutive years on 31st March, 2026, as Independent Director on the Board of Directors of the Company. Consequently, he ceases to be the Director of the Company and Member/Chairperson of the respective committees of the Board at the end of the day on 31st March, 2026.
We wish to inform you that financial results for the quarter and year ending on 31st March, 2026, along with other matters for which trading window is required to be closed from Wednesday, 1st April, 2026, till 48 hours after the announcement/ declaration of the audited financial results.
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 306.51 | 317.00 | 306.46 | 314.73 | 347.86 | 349.82 | 324.93 | 333.75 | 365.06 | 381.03 | 371.61 | 364.81 |
| YOY Revenue Growth % | 16.4% | 11.47% | 10.35% | 14.84% | 13.49% | 10.35% | 6.03% | 6.04% | 4.94% | 8.92% | 14.37% | 9.31% |
| Other Income | 3.56 | 4.17 | 4.27 | 4.89 | 5.12 | 6.05 | 5.13 | 6.35 | 6.90 | 7.37 | 7.15 | 7.33 |
| Total Income | 310.07 | 321.17 | 310.73 | 319.62 | 352.98 | 355.87 | 330.06 | 340.10 | 371.96 | 388.40 | 378.76 | 372.14 |
| Total Expenses + | 269.84 | 277.52 | 270.06 | 278.06 | 293.39 | 298.94 | 285.53 | 284.83 | 303.65 | 322.09 | 322.37 | 317.13 |
| Cost of Materials Consumed | 54.18 | 57.08 | 50.48 | 55.54 | 58.93 | 56.23 | 56.18 | 59.12 | 62.84 | 65.45 | 63.75 | 64.30 |
| Employee Benefit Expense | 63.27 | 67.07 | 66.48 | 64.79 | 66.59 | 71.61 | 72.18 | 66.72 | 64.95 | 73.58 | 74.89 | 74.18 |
| Other Expenses | 141.80 | 142.49 | 142.20 | 145.96 | 155.22 | 158.34 | 144.38 | 146.59 | 164.12 | 170.69 | 171.02 | 165.82 |
| Operating Profit | 36.67 | 39.48 | 36.40 | 36.67 | 54.47 | 50.88 | 39.40 | 48.92 | 61.41 | 58.94 | 49.24 | 47.68 |
| OPM % | 12% | 12.5% | 11.9% | 11.7% | 15.7% | 14.5% | 12.1% | 14.7% | 16.8% | 15.5% | 13.3% | 13.1% |
| Profit Before Tax + | 40.23 | 43.65 | 40.67 | 41.56 | 59.59 | 56.93 | 44.53 | 55.27 | 68.31 | 66.31 | 56.39 | 55.01 |
| Tax Expense | 9.73 | 10.80 | 11.23 | 10.39 | 14.82 | 14.53 | 11.72 | 14.26 | 16.85 | 16.85 | 15.39 | 13.31 |
| Tax % | 24.2% | 24.7% | 27.6% | 25% | 24.9% | 25.5% | 26.3% | 25.8% | 24.7% | 25.4% | 27.3% | 24.2% |
| Profit After Tax | 30.50 | 32.85 | 29.44 | 31.17 | 44.77 | 42.40 | 32.81 | 41.01 | 51.46 | 49.46 | 41.00 | 41.70 |
| EPS (Basic) | 3.33 | 3.58 | 3.21 | 3.40 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 | 5.40 | 4.47 | 4.55 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,482.51 | 1,356.36 | 1,244.70 | 1,098.67 | 888.16 | 613.38 | 830.77 |
| YOY Revenue Growth % | 9.3% | 8.97% | 13.29% | 23.7% | 44.8% | -26.17% | - |
| Other Income | 28.75 | 22.65 | 16.89 | 10.03 | 3.12 | 0.68 | 0.69 |
| Total Income | 1,511.26 | 1,379.01 | 1,261.59 | 1,108.70 | 891.28 | 614.06 | 831.46 |
| Total Expenses + | 1,265.24 | 1,162.69 | 1,095.48 | 991.52 | 812.21 | 609.77 | 744.38 |
| Cost of Materials Consumed | 256.34 | 230.46 | 217.19 | 193.61 | 173.72 | 113.85 | 151.61 |
| Employee Benefit Expense | 287.60 | 277.10 | 261.61 | 246.70 | 214.68 | 197.71 | 213.93 |
| Other Expenses | 671.65 | 604.53 | 572.54 | 507.66 | 385.46 | 261.55 | 378.84 |
| Operating Profit | 217.27 | 193.67 | 149.22 | 107.15 | 75.95 | 3.61 | 86.39 |
| OPM % | 14.7% | 14.3% | 12% | 9.8% | 8.6% | 0.6% | 10.4% |
| Profit Before Exceptional | 246.02 | 216.32 | 166.11 | 117.18 | 79.07 | 4.29 | 48.19 |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit Before Tax + | 246.02 | 216.32 | 166.11 | 117.18 | 79.07 | 4.29 | 48.19 |
| Tax Expense | 62.40 | 55.33 | 42.15 | 31.03 | 20.45 | 1.96 | 4.57 |
| Tax % | 25.4% | 25.6% | 25.4% | 26.5% | 25.9% | 45.7% | 9.5% |
| Profit After Tax | 183.62 | 160.99 | 123.96 | 86.15 | 58.62 | 2.33 | 43.62 |
| EPS (Basic) | 20.03 | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 | 4.76 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 574.77 | 420.49 | 415.26 | 332.06 | 304.28 | 290.53 | 0.00 |
| Property, Plant & Equipment | 364.48 | 327.47 | 345.89 | 274.09 | 275.15 | 279.95 | 0.00 |
| Capital Work in Progress | 2.79 | 32.52 | 0.47 | 2.53 | 0.00 | 3.34 | 0.00 |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 0.34 | 0.59 | 1.05 | 0.96 | 1.71 | 3.38 | 0.00 |
| Current Assets + | 416.59 | 431.13 | 307.98 | 223.08 | 157.43 | 141.43 | 0.00 |
| Inventories | 7.86 | 6.99 | 7.53 | 8.45 | 9.99 | 8.74 | 0.00 |
| Trade Receivables | 112.16 | 75.45 | 58.40 | 68.24 | 43.35 | 67.39 | 0.00 |
| Cash and Cash Equivalents | 4.93 | 61.48 | 61.60 | 52.26 | 41.74 | 24.92 | 0.00 |
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 740.37 | 596.68 | 477.76 | 379.45 | 325.44 | 272.76 | 0.00 |
| Equity Share Capital | 91.67 | 91.67 | 91.67 | 91.67 | 91.67 | 91.67 | 0.00 |
| Other Equity | 648.70 | 505.01 | 386.09 | 287.78 | 233.77 | 181.08 | 0.00 |
| Non-Current Liabilities | 81.44 | 76.23 | 80.06 | 46.06 | 42.77 | 43.29 | 0.00 |
| Current Liabilities | 169.55 | 178.71 | 165.42 | 129.63 | 93.50 | 115.91 | 0.00 |
| Total Liabilities | 250.99 | 254.94 | 245.48 | 175.69 | 136.27 | 159.20 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 167.44 | 156.75 | 200.15 | 144.47 | 71.29 | 27.90 | 0.00 |
| Cash from Investing Activities | -177.61 | -110.99 | -158.43 | -107.91 | -51.10 | -20.16 | 0.00 |
| Cash from Financing Activities | -46.38 | -45.88 | -32.38 | -26.04 | -3.37 | -3.15 | 0.00 |
| Net Increase/Decrease in Cash | -56.55 | -0.12 | 9.34 | 10.52 | 16.82 | 4.59 | 0.00 |